{
  "asset": "DARZALEX (daratumumab)",
  "query_terms": [
    "DARZALEX (daratumumab)",
    "daratumumab",
    "DARZALEX"
  ],
  "returned_unique": 20,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT02874742",
      "title": "Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Lenalidomide",
        "Bortezomib",
        "Dexamethasone",
        "Daratumumab"
      ],
      "last_update": "2025-02-04",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02874742"
    },
    {
      "nct_id": "NCT05408026",
      "title": "A Phase II, Multicenter, Open-Label Study of the Combination of Pomalidomide, Bortezomib, Low-Dose Dexamethasone, and Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "WITHDRAWN",
      "phase": "Phase 2",
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma"
      ],
      "lead_sponsor": "Alliance Foundation Trials, LLC.",
      "collaborators": [
        "Janssen, LP",
        "Celgene"
      ],
      "interventions": [
        "Daratumumab",
        "Pomalidomide"
      ],
      "last_update": "2023-01-27",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05408026"
    },
    {
      "nct_id": "NCT04497961",
      "title": "Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures With a Plant Based Nutrition Intervention Sub Study (NUTRIVENTION-4)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
      "collaborators": [
        "Janssen Scientific Affairs, LLC"
      ],
      "interventions": [
        "Lenalidomide",
        "Daratumumab",
        "Questionnaires",
        "Dietary Intervention"
      ],
      "last_update": "2025-09-11",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04497961"
    },
    {
      "nct_id": "NCT02076009",
      "title": "Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "phase": "Phase 3",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Daratumumab",
        "Lenalidomide",
        "Dexamethasone"
      ],
      "last_update": "2025-05-01",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02076009"
    },
    {
      "nct_id": "NCT05300451",
      "title": "A Phase II Prospective Study Evaluating the Role of Daratumumab in HLA Desensitization Prior to Transplantation",
      "overall_status": "ENROLLING_BY_INVITATION",
      "phase": "Phase 2",
      "conditions": [
        "Cardiac Transplant"
      ],
      "lead_sponsor": "Barry A. Boilson",
      "collaborators": [
        "Janssen Biotech, Inc."
      ],
      "interventions": [
        "Daratumumab and hyaluronidase-fihj"
      ],
      "last_update": "2025-10-30",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05300451"
    },
    {
      "nct_id": "NCT06918002",
      "title": "A Phase 3, Open-label, Controlled, Randomized Study of Newly Diagnosed Multiple Myeloma Treatment, Designed to Evaluate the Efficacy and Safety of the Elranatamab-lenalidomide Combination as a Replacement for Chemotherapy Followed by Autologous Stem Cell Transplant in the Consolidation Phase, and to Compare Elranatamab With Standard of Care in the Maintenance Phase",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Multiple Myeloma, Newly Diagnosed"
      ],
      "lead_sponsor": "Intergroupe Francophone du Myelome",
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Elranatamab",
        "Lenalidomide (Revlimid®)",
        "Daratumumab SC (Darzalex)",
        "Autologous Stem Cell Transplantation",
        "Bortezomib (Velcade®)",
        "Dexamethasone"
      ],
      "last_update": "2025-07-16",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06918002"
    },
    {
      "nct_id": "NCT07297563",
      "title": "A Randomized, Open-label Study To Compare The Efficacy And Safety Of Anti-CD38 Monoclonal Antibody Versus Rituximab in ITP Patients Who Failed or Relapsed After Glucocorticoid Therapy",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Immune Thrombocytopenia",
        "Treatment"
      ],
      "lead_sponsor": "Institute of Hematology & Blood Diseases Hospital, China",
      "collaborators": [],
      "interventions": [
        "Rituximab",
        "Daratumumab"
      ],
      "last_update": "2025-12-22",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07297563"
    },
    {
      "nct_id": "NCT07285239",
      "title": "Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "PrECOG, LLC.",
      "collaborators": [
        "GlaxoSmithKline"
      ],
      "interventions": [
        "Arm A: Belantamab Mafodotin",
        "Arm B: Daratumumab Hyaluronidase",
        "Bortezomib",
        "Lenalidomide",
        "Dexamethasone"
      ],
      "last_update": "2025-12-16",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07285239"
    },
    {
      "nct_id": "NCT06192979",
      "title": "Optimize First-line Treatment for Systemic Light Chain Amyloidosis With t (11; 14)",
      "overall_status": "RECRUITING",
      "phase": null,
      "conditions": [
        "Amyloidosis; Systemic",
        "AL Amyloidosis"
      ],
      "lead_sponsor": "Jin Lu, MD",
      "collaborators": [],
      "interventions": [
        "Daratumumab",
        "Bortezomib",
        "Dexamethasone",
        "Venetoclax"
      ],
      "last_update": "2024-02-06",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06192979"
    },
    {
      "nct_id": "NCT04661137",
      "title": "A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current Therapy",
      "overall_status": "SUSPENDED",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Hackensack Meridian Health",
      "collaborators": [
        "Karyopharm Therapeutics Inc"
      ],
      "interventions": [
        "Selinexor 60 MG",
        "Selinexor 80 MG",
        "Selinexor 100 MG",
        "Carfilzomib",
        "Pomalidomide",
        "Daratumumab",
        "Dexamethasone"
      ],
      "last_update": "2025-02-25",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04661137"
    }
  ]
}